MRI for the initial staging of MIBC is both feasible and beneficial in reducing treatment delays compared to TURBT, a new study shows.
Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.
Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback